CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy

Chien Chih Ke, Ren Shyan Liu, An Hang Yang, Ching Sheng Liu, Chin Wen Chi, Ling Ming Tseng, Yi Fan Tsai, Jennifer H. Ho, Chen Hsen Lee, Oscar K. Lee

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: 131I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characteristics of stem cells and have the ability to initiate tumours. However, no studies have addressed the influence of CD133-expressing cells on radioiodide therapy of the thyroid cancer. The aim of this study was to investigate whether CD133 + cells contribute to the radioresistance of thyroid cancer and thus potentiate future recurrence and metastasis. Methods: Thyroid cancer cell lines were analysed for CD133 expression, radiosensitivity and gene expression. Results: The anaplastic thyroid cancer cell line ARO showed a higher percentage of CD133+ cells and higher radioresistance. After γ-irradiation of the cells, the CD133+ population was enriched due to the higher apoptotic rate of CD133- cells. In vivo 131I treatment of ARO tumour resulted in an elevated expression of CD133, Oct4, Nanog, Lin28 and Glut1 genes. After isolation, CD133+ cells exhibited higher radioresistance and higher expression of Oct4, Nanog, Sox2, Lin28 and Glut1 in the cell line or primarily cultured papillary thyroid cancer cells, and lower expression of various thyroid-specific genes, namely NIS, Tg, TPO, TSHR, TTF1 and Pax8. Conclusion: This study demonstrates the existence of CD133-expressing thyroid cancer cells which show a higher radioresistance and are in an undifferentiated status. These cells possess a greater potential to survive radiotherapy and may contribute to the recurrence of thyroid cancer. A future therapeutic approach for radioresistant thyroid cancer may focus on the selective eradication of CD133+ cells.

Original languageEnglish
Pages (from-to)61-71
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Thyroid Neoplasms
Therapeutics
Cell Line
Recurrence
Neoplastic Stem Cells
Radiation Tolerance
Genes
Neoplasms
Thyroid Gland
Radiotherapy
Stem Cells
Neoplasm Metastasis
Gene Expression

Keywords

  • I
  • Cancer stem cell
  • CD133
  • Radiotherapy
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. / Ke, Chien Chih; Liu, Ren Shyan; Yang, An Hang; Liu, Ching Sheng; Chi, Chin Wen; Tseng, Ling Ming; Tsai, Yi Fan; Ho, Jennifer H.; Lee, Chen Hsen; Lee, Oscar K.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 40, No. 1, 01.2013, p. 61-71.

Research output: Contribution to journalArticle

Ke, Chien Chih ; Liu, Ren Shyan ; Yang, An Hang ; Liu, Ching Sheng ; Chi, Chin Wen ; Tseng, Ling Ming ; Tsai, Yi Fan ; Ho, Jennifer H. ; Lee, Chen Hsen ; Lee, Oscar K. / CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. In: European Journal of Nuclear Medicine and Molecular Imaging. 2013 ; Vol. 40, No. 1. pp. 61-71.
@article{58bf093d60a843cf87b9659d8f7d3ffe,
title = "CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy",
abstract = "Purpose: 131I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characteristics of stem cells and have the ability to initiate tumours. However, no studies have addressed the influence of CD133-expressing cells on radioiodide therapy of the thyroid cancer. The aim of this study was to investigate whether CD133 + cells contribute to the radioresistance of thyroid cancer and thus potentiate future recurrence and metastasis. Methods: Thyroid cancer cell lines were analysed for CD133 expression, radiosensitivity and gene expression. Results: The anaplastic thyroid cancer cell line ARO showed a higher percentage of CD133+ cells and higher radioresistance. After γ-irradiation of the cells, the CD133+ population was enriched due to the higher apoptotic rate of CD133- cells. In vivo 131I treatment of ARO tumour resulted in an elevated expression of CD133, Oct4, Nanog, Lin28 and Glut1 genes. After isolation, CD133+ cells exhibited higher radioresistance and higher expression of Oct4, Nanog, Sox2, Lin28 and Glut1 in the cell line or primarily cultured papillary thyroid cancer cells, and lower expression of various thyroid-specific genes, namely NIS, Tg, TPO, TSHR, TTF1 and Pax8. Conclusion: This study demonstrates the existence of CD133-expressing thyroid cancer cells which show a higher radioresistance and are in an undifferentiated status. These cells possess a greater potential to survive radiotherapy and may contribute to the recurrence of thyroid cancer. A future therapeutic approach for radioresistant thyroid cancer may focus on the selective eradication of CD133+ cells.",
keywords = "I, Cancer stem cell, CD133, Radiotherapy, Thyroid cancer",
author = "Ke, {Chien Chih} and Liu, {Ren Shyan} and Yang, {An Hang} and Liu, {Ching Sheng} and Chi, {Chin Wen} and Tseng, {Ling Ming} and Tsai, {Yi Fan} and Ho, {Jennifer H.} and Lee, {Chen Hsen} and Lee, {Oscar K.}",
year = "2013",
month = "1",
doi = "10.1007/s00259-012-2242-5",
language = "English",
volume = "40",
pages = "61--71",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy

AU - Ke, Chien Chih

AU - Liu, Ren Shyan

AU - Yang, An Hang

AU - Liu, Ching Sheng

AU - Chi, Chin Wen

AU - Tseng, Ling Ming

AU - Tsai, Yi Fan

AU - Ho, Jennifer H.

AU - Lee, Chen Hsen

AU - Lee, Oscar K.

PY - 2013/1

Y1 - 2013/1

N2 - Purpose: 131I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characteristics of stem cells and have the ability to initiate tumours. However, no studies have addressed the influence of CD133-expressing cells on radioiodide therapy of the thyroid cancer. The aim of this study was to investigate whether CD133 + cells contribute to the radioresistance of thyroid cancer and thus potentiate future recurrence and metastasis. Methods: Thyroid cancer cell lines were analysed for CD133 expression, radiosensitivity and gene expression. Results: The anaplastic thyroid cancer cell line ARO showed a higher percentage of CD133+ cells and higher radioresistance. After γ-irradiation of the cells, the CD133+ population was enriched due to the higher apoptotic rate of CD133- cells. In vivo 131I treatment of ARO tumour resulted in an elevated expression of CD133, Oct4, Nanog, Lin28 and Glut1 genes. After isolation, CD133+ cells exhibited higher radioresistance and higher expression of Oct4, Nanog, Sox2, Lin28 and Glut1 in the cell line or primarily cultured papillary thyroid cancer cells, and lower expression of various thyroid-specific genes, namely NIS, Tg, TPO, TSHR, TTF1 and Pax8. Conclusion: This study demonstrates the existence of CD133-expressing thyroid cancer cells which show a higher radioresistance and are in an undifferentiated status. These cells possess a greater potential to survive radiotherapy and may contribute to the recurrence of thyroid cancer. A future therapeutic approach for radioresistant thyroid cancer may focus on the selective eradication of CD133+ cells.

AB - Purpose: 131I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characteristics of stem cells and have the ability to initiate tumours. However, no studies have addressed the influence of CD133-expressing cells on radioiodide therapy of the thyroid cancer. The aim of this study was to investigate whether CD133 + cells contribute to the radioresistance of thyroid cancer and thus potentiate future recurrence and metastasis. Methods: Thyroid cancer cell lines were analysed for CD133 expression, radiosensitivity and gene expression. Results: The anaplastic thyroid cancer cell line ARO showed a higher percentage of CD133+ cells and higher radioresistance. After γ-irradiation of the cells, the CD133+ population was enriched due to the higher apoptotic rate of CD133- cells. In vivo 131I treatment of ARO tumour resulted in an elevated expression of CD133, Oct4, Nanog, Lin28 and Glut1 genes. After isolation, CD133+ cells exhibited higher radioresistance and higher expression of Oct4, Nanog, Sox2, Lin28 and Glut1 in the cell line or primarily cultured papillary thyroid cancer cells, and lower expression of various thyroid-specific genes, namely NIS, Tg, TPO, TSHR, TTF1 and Pax8. Conclusion: This study demonstrates the existence of CD133-expressing thyroid cancer cells which show a higher radioresistance and are in an undifferentiated status. These cells possess a greater potential to survive radiotherapy and may contribute to the recurrence of thyroid cancer. A future therapeutic approach for radioresistant thyroid cancer may focus on the selective eradication of CD133+ cells.

KW - I

KW - Cancer stem cell

KW - CD133

KW - Radiotherapy

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84875726875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875726875&partnerID=8YFLogxK

U2 - 10.1007/s00259-012-2242-5

DO - 10.1007/s00259-012-2242-5

M3 - Article

C2 - 23081821

AN - SCOPUS:84875726875

VL - 40

SP - 61

EP - 71

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 1

ER -